Likelihood of Approval and Phase Transition Success Rate Model – Xgeva in Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Xgeva in Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Xgeva in Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) Drug Details:
Denosumab (Xgeva / Ranmark / Corora, Ganvado, Zerount) is a human monoclonal antibody of the immunoglobulin G2 (IgG2), acts as antineoplastic agent. It is produced in genetically engineered Chinese hamster ovary cells. It is formulated as solution, powder for solution for subcutaneous route of administration. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases in patients with multiple myeloma and giant cell tumor of bone. Xgeva is also indicated for the treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months and is indicated for the treatment of adults and skeletally mature adolescents (defined as having at least one mature long bone and weigh=45 kg) with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity.The drug candidate is under development for the treatment of nasopharyngeal cancer, multiple myeloma, metastatic melanoma, langerhans cell histiocytosis (LCH), metastatic urothelial carcinoma and metastatic renal cell carcinoma. It was also under development for the treatment of breast cancer in Japan and metastatic breast cancer. (adjuvant therapy), bone metastasis.It was also under development for the treatment of osteogenesis imperfecta and metastatic non-small cell lung cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Xgeva LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports